JAK2 and COVID-19: Notably, elevated IL-6 levels have also been associated with hypercoagulability in patients with COVID-19.[23] Baricitinib is an IL-6 receptor antibody that exhibits antiviral activity at a tolerable therapeutic dose range by inhibiting JAK1/JAK2 enzyme activity.